Join our daily newsletter At The Bell to receive exclusive market insights
Firebrick Pharma (ASX:FRE) has inked a deal with Guardian, a pharmacy chain in Singapore, to launch retail sales of its Nasodine product.
The antiseptic nasal spray – think ‘Betadine’ when it comes to the name – has been the company’s flagship offering for a while now, advertises on its website as “the spray that kills germs.”
The spray does not necessarily target any one condition but instead lends itself to being a nasal spray analogue for alcoholic hand wash.
It’s more about satisfying potential user concerns after spending time on public transport and in office buildings, for example, one could be exposing oneself to other people’s germs – an interesting product to watch.
Firebrick expects its Nasodine to be available in all of Guardian’s 121 stores across Singapore – including, the company specifically highlighted, six at Changi Airport.
(This, Firebrick is clearly hopeful, is where it can really tap into a desirable consumer psychology.)
Stock is expected to hit the shelves from January next year with delivery to Firebrick’s Singaporean distro slated for next month.
“Firebrick management will assist in the training of Guardian retail pharmacists to sell Nasodine to consumers,” the company wrote on Monday.
Firebrick also recently hired former Johnson & Johnson executive Keith Shortall, whom was tasked with launching the product in Singapore by June next year – so management is painting this as a fast-track win.
“With the expansion of Nasodine marketing from online only sales to promotion through HCPs and now through Guardian pharmacies, we are very optimistic about the potential for sales growth in 2025,” FRE EC Dr. Peter Molloy said.
FRE last traded at 5.3cps.
Join the discussion: See what HotCopper users are saying about Firebrick and be part of the conversations that move the markets.
